Christopher Buckley DPhil, FRCP, MBBS

Chris Buckley is the Kennedy Professor of Translational Rheumatology at the Universities of Birmingham and Oxford. He is Director of Clinical Research at the Kennedy Institute of Rheumatology in Oxford and Director of NIHR Infrastructure for Birmingham Health Partners. He leads the Arthritis Therapy Acceleration Programme (A-TAP) which aims to deliver “stratified pathology” in a range of immune-mediated inflammatory diseases in order to choose the right disease indication for the right drug. This approach complements stratified medicine where the aim is to choose the right drug for the right patient. His laboratory explores the role of fibroblasts in driving disease progression and tissue tropism in Immune-Mediated Inflammatory Diseases.

Chris is part of the Modality Partnership, a single GP organisation that operates across 35 different locations as the first national GP super-partnership in the UK. A super-partnership is an organisation that combines the advantages of small GP practices working closely in local communities, with the medical and technological opportunities of larger-scale operation. Modality is dedicated to improving healthcare provision and extending the opportunity for patients in primary care to take part in experimental medicine studies by operating at a larger scale.

Chris has made major contributions to scientific administration through his roles with the Arthritis Research UK (Chair of the Fellowship Committee as well as EULAR (Scientific Programme organizing committee). He is closely involved in the development of clinical academics and he is a strong and eloquent advocate for clinician-scientists in several fora.